


PENDING**(IN202311002668)**

Quinazoline based compounds and pharmaceutical compositions thereof



NEED

Malaria, cancer, and tuberculosis treatments face high resistance, limiting treatment effectiveness. Drug discovery is slowed by outdated compounds that struggle with specificity. What if there were a new, potent solution that addressed multiple diseases?

TECHNOLOGY OVERVIEW

This invention focuses on quinazoline-based compounds designed to treat malaria, cancer, tuberculosis, and their combinations. The compounds' structure allows for enhanced interaction with biological targets, potentially offering broad-spectrum therapeutic activity. These compounds also provide stability for pharmaceutical formulations.

TECHNOLOGY KEY FEATURES

Quinazoline compounds exhibit broad-spectrum activity against malaria, cancer, and tuberculosis. Their unique structural diversity allows for enhanced bioactivity. They are also designed for ease of pharmaceutical formulation, improving efficacy in treating multi-disease conditions.

[Read more here](#)

MARKET ANALYSIS

The global oncology drug market is projected to grow at 7.5% CAGR, reaching USD 320 billion by 2033. Similarly, the global anti-tuberculosis drug market is expected to grow at 5.2% CAGR, reaching USD 1.5 billion by 2033. (Source: Grand View Research, 2023)

Target Industries

Pharmaceutical manufacturers focusing on multi-disease treatments; companies specializing in anti-cancer, anti-malaria, and anti-TB drug formulations; R&D enterprises developing novel molecular therapies for tropical diseases and cancer

AT A GLANCE

- SDG 3: Good Health and Well-being; SDG 9: Industry, Innovation and Infrastructure

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,
BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913